Blog
RSS FeedPosted by Michael Wonder on 03 May 2022
Unwanted advice? Frequency, characteristics and outcomes of negative advisory committee votes for FDA approved drugs
2 May 2022 - Substantial controversy arose in 2021 when the FDA approved the Alzheimer’s disease drug aducanumab (Aduhelm) under its ...
Posted by Michael Wonder on 16 Mar 2021
Once again, the viability of the U.S. biosimilar market is thrown into question
15 March 2021 - Despite periodic reports that biosimilars have finally arrived and will save the U.S. health care system ...